Clinical trials: Early Stage Breast Carcinoma
ER+HER2- Breast Cancer
SKB264 Combined With KL-A167 Neoadjuvant Therapy for Early-stage, High-risk ER+/HER2- Breast Cancer
This study aimed to evaluate the efficacy and safety of SKB264 combined with KL-A167 as neoadjuvant therapy in early-stage high-risk ER+HER2- breast cancer patients.
- Trial name
- NeoSaciA (NCT07109284)
- Testing
- Sacituzumab tirumotecan, Tagitanlimab
- Volunteers
- 55 people
- Sponsor
- West China Hospital
Ductal Breast Carcinoma In Situ, Estrogen Receptor Positive
Accelerated Partial Breast Radiation Therapy Using High-Dose Rate Brachytherapy in Treating Patients With Early Stage Breast Cancer After Surgery
This phase II trial studies how well accelerated partial breast irradiation (APBI) using high-dose rate (HDR) brachytherapy works in treating patients with breast cancer that has not spread beyond the breast or the axillary lymph…
- Conditions
- Ductal Breast Carcinoma In Situ, Estrogen Receptor Positive, Invasive Breast Carcinoma, Progesterone Receptor Positive
- Trial name
- TRIUMPH-T (NCT02526498)
- Testing
- Accelerated Partial Breast Irradiation, High-Dose Rate Brachytherapy, Questionnaire Administration
- Where
- 10 sites in United States
- Volunteers
- 200 people
- Sponsor
- Rutgers, The State University of New Jersey
HER2-positive Breast Cancer
Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging
The purpose of the study is to see if a new group of imaging tests can help identify response to stage IV HER2+ breast cancer before treatment.
- Trial name
- NCT04273555
- Testing
- [18F]-FDG
- Where
- United States
- Sponsor
- University of Alabama at Birmingham
Breast Cancer
Comparing (SIS.NET) to Standard Care in Patients Who Have Completed the Acute Phase of Treatment for Early Breast Cancer
This is a pilot study that will compare two systems of breast cancer follow up care and will evaluate a number of parameters indicating quality and efficiency of care delivery as well as patient satisfaction with care.
- Trial name
- CC077515 (NCT01308775)
- Testing
- SIS.NET, Routine Follow-up
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- University of California, San Francisco
Breast Cancer Invasive, Hormone-receptor-positive Breast Cancer
Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer
This is a multi-center, open-lable, prospective, randomized phase III clinical trial to further validate the efficacy and safety of neoadjuvant pyrotinib combined with chemotherapy in HR-positive/HER2-low (IHC 2+/FISH-negative)…
- Conditions
- Breast Cancer Invasive, Hormone-receptor-positive Breast Cancer, HER2 Low Breast Carcinoma, Early-stage Breast Cancer
- Trial name
- NCT06144944
- Testing
- Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel, Epirubicin or doxorubicin, cyclophosphamide, paclitaxel
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Cancer
Radiation Therapy During Surgery in Treating Older Women With Invasive Breast Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation during surgery may be an effective treatment for breast cancer.
- Trial name
- NRR (NCT00182728)
- Testing
- surgery, therapy, radiation therapy
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Breast Cancer
Docetaxel Followed by CEF (Cyclophosphamide, Epirubicin and 5-Fluorouracil) Compared to Docetaxel and Capecitabine Followed by CEX (Cyclophosphamide, Epirubicin and Capecitabine) as Adjuvant Treatment for Breast Cancer
This study compares two chemotherapy regimens as adjuvant treatment for breast cancer. The study participants are randomly allocated to receive either 3 cycles of docetaxel followed by 3 cycles of CEF (cyclophosphamide…
- Trial name
- NCT00114816
- Testing
- capecitabine, docetaxel
- Where
- Finland
- Volunteers
- 1,500 people
- Sponsor
- Finnish Breast Cancer Group
TNBC
A Single-Arm, Single-Center, Phase II Clinical Study of Camrelizumab Combined With Radiochemotherapy as Neoadjuvant Therapy for Early-Stage Triple-Negative Breast Cancer
Camrelizumab + Chemoradiotherapy for Early TNBC Sponsor/Leading Center: Tianjin Medical University Cancer Institute and Hospital Study Type: Single-arm, single-center, Phase Ⅱ clinical study Planned Enrollment: 43 patients…
- Trial name
- NCT07491822
- Testing
- treatment group
- Volunteers
- 43 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Breast Cancer, Estrogen Receptor Positive Tumor
To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH)
This is a phase II open-label, multicentre, randomized trial. The study assesses the treatment of postmenopausal patients with hormone receptor positive/HER2 positive early breast cancer with neoadjuvant palbociclib in…
- Conditions
- Breast Cancer, Estrogen Receptor Positive Tumor, HER2-positive Breast Cancer
- Trial name
- TOUCH (NCT03644186)
- Testing
- Paclitaxel, Trastuzumab, Pertuzumab
- Where
- 54 sites in Belgium, France and 2 more
- Volunteers
- 147 people
- Sponsor
- ETOP IBCSG Partners Foundation
Breast Neoplasms, Breast Cancer
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
This study will look at the efficacy and safety of trastuzumab deruxtecan (T-DXd) in a neoadjuvant setting, in high-risk, HER2-positive early non-metastatic breast cancer.
- Conditions
- Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer
- Trial name
- NCT05113251
- Testing
- Trastuzumab Deruxtecan, Paclitaxel, Trastuzumab
- Where
- 145 sites in United States, Brazil and 16 more
- Volunteers
- 927 people
- Sponsor
- AstraZeneca
Early Stage Breast Cancer
Cyberknife for Early Stage Breast Cancer
This phase II study based on the Cyberknife Society study will evaluate the technical feasibility and acute toxicity of Partial Breast Irradiation (PBI) with the Cyberknife.
- Trial name
- NCT03946683
- Testing
- Cyberknife for Early Stage Breast Cancer
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- NYU Langone Health
Female Breast Cancer
Ultra-hypofractionated Radiotherapy in Breast Cancer Patients
The present multicenter, retrospective and prospective observational study, aims to evaluate an ultra-hypofractionated whole breast irradiation schedule (WBI, 26 Gy in 5 fractions), in order to confirm literature data (FAST-F…
- Trial name
- NCT05586256
- Testing
- ultra-hypofractionated whole breast irradiation
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- University Of Perugia
Breast Cancer, Breast Neoplasms
A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer
This is a phase III, double-blind, randomized, parallel-controlled, multicenter equivalence study to compare the efficacy and safety of pertuzumab biosimilar HLX11 vs.
- Conditions
- Breast Cancer, Breast Neoplasms, HER2-positive Breast Cancer
- Trial name
- NCT05346224
- Testing
- HLX11, EU-Perjeta®
- Where
- 79 sites in China, Hungary and 2 more
- Volunteers
- 900 people
- Sponsor
- Shanghai Henlius Biotech
Breast Cancer Metastatic
Zoledronic Acid Combined With EC-T for Triple-Negative Breast Cancer
Exploring the efficacy and safety of zoledronic acid combined with neoadjuvant chemotherapy (EC-T) in neoadjuvant treatment for early-stage or locally advanced triple-negative breast cancer, the trial protocol of zoledronic acid…
- Trial name
- NCT06876636
- Testing
- Zoledronic Acid Combined with Neoadjuvant Chemotherapy (EC-T)
- Where
- China
- Volunteers
- 99 people
- Sponsor
- Xijing Hospital
Early-Stage Breast Cancer, Neoadjuvant Therapy
COGNITION: Genomics-Guided Precision Oncology in Early High-Risk Breast Cancer
The COGNITION diagnostic platform elucidates the biomarker profile of neoadjuvant chemotherapy-resistant residual bulk tumors in high risk early breast cancer patients.
- Trial name
- COGNITION (NCT05906407)
- Testing
- Genomic Profiling / Sequencing
- Where
- 12 sites in Germany
- Volunteers
- 2,000 people
- Sponsor
- German Cancer Research Center
Early Stage Breast Carcinoma
EXamining PErsonalised Radiation Therapy for Low-risk Early Breast Cancer
This is a randomised, phase III, non-inferiority trial evaluating radiation therapy versus observation following breast conserving surgery and planned endocrine therapy in patients with stage I breast cancer of luminal A subtype…
- Trial name
- EXPERT (NCT02889874)
- Testing
- Omission of radiation therapy
- Where
- 68 sites in Argentina, Australia and 7 more
- Volunteers
- 1,167 people
- Sponsor
- Breast Cancer Trials, Australia and New Zealand
Breast Neoplasms, Breast Cancer
Evaluating and Comparing Two Surgical Methods for Treatment of Early Stage Breast Cancer
The goal of this study is to compare two different types of breast surgery. In the first type, the doctor removes only the tumor.
- Conditions
- Breast Neoplasms, Breast Cancer, Breast Tumors, Cancer of Breast
- Trial name
- NCT01271738
- Testing
- Remove tumor only, Removal of tumor and tissue
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- Emory University
Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma
Breast Cancer WEight Loss Study (BWEL Study)
This randomized phase III trial compares whether weight loss in overweight and obese women may prevent breast cancer from coming back (recurrence).
- Conditions
- Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7
- Trial name
- NCT02750826
- Testing
- Health Education Program, Weight Loss Intervention
- Where
- 1,498 sites in United States, Canada and 2 more
- Volunteers
- 3,177 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer, HER2 + Breast Cancer
Efficacy of TQB2102 Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer.
The aim of this study is to evaluate the efficacy and safety of TQB2102 compared to TCbHP in the neoadjuvant treatment of HER2-positive breast cancer.
- Trial name
- NCT07136974
- Testing
- TQB2102, Docetaxel + Carboplatin + Trastuzumab +Pertuzumab
- Where
- China
- Volunteers
- 280 people
- Sponsor
- Henan Cancer Hospital
Breast Cancer
Partial Breast Irradiation Using Accelerated Intensity Modulated Radiotherapy
This is a phase I- II feasibility study for delivering partial breast irradiation (PBI) in selected patients with early stage, lymph node negative, breast cancer after breast-conserving surgery using accelerated Intensity…
- Trial name
- NCT00581529
- Testing
- IMRT
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of Michigan Rogel Cancer Center